Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
:URGN
URGN Stock Chart & Stats
$25.87
-$0.02(-0.18%)
At close: 4:00 PM EST
$25.87
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$3.42 - $26.28
Previous CloseN/A
Volume157.75K
Average Volume (3M)1.21M
Market Cap
$1.21B
Enterprise Value$960.30M
Total Cash (Recent Filing)$127.03M
Total Debt (Recent Filing)$129.94M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Mar 12, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding46,808,890
10 Day Avg. Volume1,307,740
30 Day Avg. Volume1,213,093
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-51.87
Price to Sales (P/S)5.05
P/FCF Ratio-4.70
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue13.28
Enterprise Value/Gross Profit14.95
Enterprise Value/Ebitda-10.54
Forecast
1Y Price Target
$39.40Price Target Upside52.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.18
Revenue Forecast (FY)$113.40M
Bulls Say, Bears Say
Bulls Say
Earnings And Revenue GrowthStrong initial demand should translate to Q4 inflection with more to follow the permanent J code, leading to more rapid and robust revenue recording.
Market DemandUroGen management indicated strong market demand for ZUSDURI, as evidenced by roughly $4.5M in preliminary demand revenue estimated during the month of October 2025 alone.
Regulatory ApprovalThe strong, consistent UGN-103 data support a filing next year per the FDA to provide life cycle management well ahead of Zusduri's LOE.
Bears Say
Urogen Pharma News
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $3.42 and its highest was $26.28 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $1.21B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Mar 12, 2026 which is in 107 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Nov 06, 2025. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.692 by $0.002.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.48.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 46,808,890 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.692. Following the earnings report the stock price went up 21.906%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.40 (52.30% Upside)
$39.40 (52.30% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 500.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
123.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.71%
Trailing 12-Months
Company Description
Urogen Pharma
Urogen Pharma Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological diseases. The company specializes in the research and development of products designed to treat conditions such as bladder cancer and other urological disorders, leveraging its proprietary technology platforms to create targeted therapies. Urogen's core products include its lead investigational therapies, which aim to improve patient outcomes and enhance the quality of life for individuals suffering from these conditions.
URGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a balanced view with strong progress in the ZUSDURI launch and JELMYTO revenue growth, offset by challenges in operational execution and increased expenses. The permanent J-code for ZUSDURI is anticipated to drive future growth, but current operational delays and increased net loss are notable concerns.View all URGN earnings summariesURGN Stock 12 Month Forecast
Average Price Target
$39.40
▲(52.30% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
1.99% Insiders
2.66% Mutual Funds
45.60% Other Institutional Investors
43.24% Public Companies and Individual Investors